Cinobufaginol |
| Catalog No.GC35697 |
Cinobufaginol은 두꺼비 독에서 분리된 천연 부파디에놀리드로 중국에서 수세기 동안 다양한 질병, 특히 암을 치료하는 데 널리 사용되었습니다. Cinobufaginol은 803 μμ의 IC50으로 인간 비인두 암종 세포주에 대한 활성을 강력하게 억제합니다. 및 1.270 μμ 각각 CNE-1 및 CNE-2Z용입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 6691-83-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Cinobufaginol is a natural bufadienolide isolated from toad venom which has been widely used for centuries in China to treat different diseases, especially for cancer. Cinobufaginol potently inhibits the activity against human nasopharyngeal carcinoma cell lines with IC50s of 803 μμ and 1.270 μμ for CNE-1 and CNE-2Z, respectively[1].
[1]. Liu JS, et al. Anti-tumor effects and 3D-quantitative structure-activity relationship analysis of bufadienolidesfrom toad venom. Fitoterapia. 2019 Apr;134:362-371.
| Cas No. | 6691-83-4 | SDF | |
| Canonical SMILES | O=C(C=C1)OC=C1[C@H]2[C@@H](OC(C)=O)[C@@]3([H])[C@]4(O3)[C@]5([H])CC[C@]6([H])C[C@@H](O)CC[C@]6(CO)[C@@]5([H])CC[C@]24C | ||
| Formula | C26H34O7 | M.Wt | 458.54 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1808 mL | 10.9042 mL | 21.8083 mL |
| 5 mM | 436.2 μL | 2.1808 mL | 4.3617 mL |
| 10 mM | 218.1 μL | 1.0904 mL | 2.1808 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *